Millipore Sigma Vibrant Logo

OP64 Anti-p21WAF1 (Ab-1) Mouse mAb (EA10)

This Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) is validated for use in FC, Immunoblotting, IF, IP, Paraffin Sections for the detection of p21WAF1 (Ab-1).

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Anti-CIP1, Anti-SD11, Anti-p21, Anti-WAF

View Products on Sigmaaldrich.com
OP64
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
OP64-100UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 100 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewRecognizes the ~21 kDa p21WAF1 protein in skin and colon tissue and in cells expressing wild-type p53 (e.g. Hs27 or U205 cells treated with DNA damaging agents).
      Catalogue NumberOP64
      Brand Family Calbiochem®
      SynonymsAnti-CIP1, Anti-SD11, Anti-p21, Anti-WAF
      Application Data
      Detection of p21 WAF1 by immunoblotting: Sample: Whole cell lysate (56 µg) from MCF-7 cells. Primary antibody: Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) (Cat. No. OP64) (3 µg/ml). Secondary antibody: Anti-Mouse IgG (Goat) Peroxidase Conjugate. Detection: chemiluminescence.
      References
      ReferencesAgarwal, M.L., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 8493.
      Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
      Deng, C., et al. 1995. Cell 82, 675.
      El-Deiry, W.S., et al. 1995. Cancer Res. 55, 2910.
      Waldman, T., et al. 1995. Cancer Res. 55, 5187.
      Elbendary, A., et al.1994. Cell Growth Diff. 5, 1301.
      El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
      Li, R., et al. 1994. Nature 371, 534.
      Michieli, P., et al. 1994. Cancer Res. 54, 3391.
      Noda, A., et al.1994. Exp. Cell Res. 211, 90.
      El-Deiry, W.S., et al.1993. Cell 75, 817.
      Gu, Y., et al. 1993. Nature 366, 707.
      Harper, J.W., et al.1993. Cell 75, 805.
      Xiong, Y., et al.1993. Genes Devel. 7, 1572.
      Xiong, Y., et al.1993. Nature 366, 701.
      Xiong, Y., et al.1992. Cell 71, 505.
      Product Information
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Negative controlUnstimulated cells, unstimulated skin tissue, or SK-OV-3 cells
      Positive controlAny cell line expressing wild-type p53 (e.g. Hs27 or U2OS treated with DNA-damaging agents) or skin or colon tissue
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesEpitope Identification Patrick O'Connor (NCI, personal communication). Original Clone, Paraffin Sections, Frozen Sections El-Deiry, W.S., et al. 1995. Cancer Res. 55, 2910. Paraffin Sections, Antigen Retrieval Mouriaux, Frédéric, et al. 2000. Invest Ophthamol. Vis. Sci. 41, 2837. Flow Cytometry Carter, A., et al. 2004. Brit. J. Haematol. 127, 425.
      Key Applications Flow Cytometry
      Frozen Sections
      Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Paraffin Sections
      Application NotesFlow Cytometry (2 µg/ml or use Cat. No. OP64F; see application references)
      Frozen Sections (5 µg/ml or use Cat. No. OP64F)
      Immunoblotting (1-3 µg/ml)
      Immunofluorescence (1-5 µg/ml or use Cat. No. OP64F)
      Immunoprecipitation (2 µg/sample)
      Paraffin Sections (5 µg/ml or use OP64F; heat pre-treatment required; see comments and application references)
      Application CommentsMaximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS or MCF7 cells with DNA damaging agents (such as doxorubicin at 0.2 µg/ml) induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. Untreated cells will express little p21WAF1 and can be used as a negative control. Cat. No. OP64F was tested in HALT cells induced by incubation at 31°C; FITC-goat anti-mouse IgG (Cat. No. DC13L) was used as a negative control. This antibody will immunoprecipitate p21WAF1 but not associated proteins. For immunoblotting applications, use a 0.22 µm filter and visualize by chemiluminescence. For staining paraffin sections, heating the tissue in 10 mM citrate buffer is required (see application references). In either paraffin or frozen sections of normal human colon, the non-dividing cells of colonic epithelium will stain positive for p21WAF1 while the proliferating compartment of crypts will not stain. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenfull-length, recombinant, human p21WAF1
      ImmunogenHuman
      Epitopewithin amino acids 58-77 of human p21WAF1
      CloneEA10
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      OP64-100UG 07790788053918

      Documentation

      Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) Certificados de análisis

      CargoNúmero de lote
      OP64

      Referencias bibliográficas

      Visión general referencias
      Agarwal, M.L., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 8493.
      Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
      Deng, C., et al. 1995. Cell 82, 675.
      El-Deiry, W.S., et al. 1995. Cancer Res. 55, 2910.
      Waldman, T., et al. 1995. Cancer Res. 55, 5187.
      Elbendary, A., et al.1994. Cell Growth Diff. 5, 1301.
      El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
      Li, R., et al. 1994. Nature 371, 534.
      Michieli, P., et al. 1994. Cancer Res. 54, 3391.
      Noda, A., et al.1994. Exp. Cell Res. 211, 90.
      El-Deiry, W.S., et al.1993. Cell 75, 817.
      Gu, Y., et al. 1993. Nature 366, 707.
      Harper, J.W., et al.1993. Cell 75, 805.
      Xiong, Y., et al.1993. Genes Devel. 7, 1572.
      Xiong, Y., et al.1993. Nature 366, 701.
      Xiong, Y., et al.1992. Cell 71, 505.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision12-March-2008 JSW
      SynonymsAnti-CIP1, Anti-SD11, Anti-p21, Anti-WAF
      ApplicationFlow Cytometry (2 µg/ml or use Cat. No. OP64F; see application references)
      Frozen Sections (5 µg/ml or use Cat. No. OP64F)
      Immunoblotting (1-3 µg/ml)
      Immunofluorescence (1-5 µg/ml or use Cat. No. OP64F)
      Immunoprecipitation (2 µg/sample)
      Paraffin Sections (5 µg/ml or use OP64F; heat pre-treatment required; see comments and application references)
      Application Data
      Detection of p21 WAF1 by immunoblotting: Sample: Whole cell lysate (56 µg) from MCF-7 cells. Primary antibody: Anti-p21WAF1 (Ab-1) Mouse mAb (EA10) (Cat. No. OP64) (3 µg/ml). Secondary antibody: Anti-Mouse IgG (Goat) Peroxidase Conjugate. Detection: chemiluminescence.
      DescriptionPurified mouse monoclonal antibody generated by immunizing F1 mice with the specified immunogen and fusing splenocytes with SP2/0 mouse myeloma cells (see application references). Recognizes the ~21 kDa p21WAF1 protein.
      BackgroundThe tumor suppressor p53 transcriptionally activates a number of genes including the WAF1/CIP1 gene in response to DNA damage. The ~21 kDa product of the WAF1 gene is found in a complex involving cyclins, cyclin dependent kinases (CDK), and PCNA in normal cells but not transformed cells and appears to be a universal inhibitor of CDK activity. One consequence of p21WAF1 binding to and inhibiting CDKs is to prevent CDK-dependent phosphorylation and subsequent inactivation of the Rb protein which is essential for cell cycle progression. p21WAF1 is, therefore, a potent and reversible inhibitor of cell cycle progression at both the G1 and G2 checkpoints, presumably to allow sufficient time for DNA repair to be completed. Irreversible G1 or G2 arrest leads to apoptosis. However, the role of p21WAF1 in apoptosis is less clear although p53-mediated apoptosis leads to increased WAF1 expression. Induction of p21WAF1 in response to DNA damage can occur by both p53-dependent and p53-independent mechanisms, in response to mitogenic stimuli, differentiation, or in tumor cells with mutated p53. Functional p21WAF1 is essential for p53-mediated G1 arrest presumably due to WAF1 inhibition of both CDK activity and PCNA-dependent DNA replication. WAF1 has also been identified as a gene involved in cellular senescence, termed sdi1. Not surprisingly, p21WAF1 overexpression is growth suppressive, consistent with its role as an inhibitor of CDKs. By inhibiting Rb inactivation in a p53-dependent fashion, p21WAF1 serves to integrate cell cycle control mediated by p53 and Rb.
      HostMouse
      Immunogen speciesHuman
      Immunogenfull-length, recombinant, human p21WAF1
      Epitopewithin amino acids 58-77 of human p21WAF1
      CloneEA10
      IsotypeIgG₁
      Specieshuman, not mouse, not rat
      Positive controlAny cell line expressing wild-type p53 (e.g. Hs27 or U2OS treated with DNA-damaging agents) or skin or colon tissue
      Negative controlUnstimulated cells, unstimulated skin tissue, or SK-OV-3 cells
      FormLiquid
      FormulationIn 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsMaximal p21WAF1 expression requires wild type p53 activity. Treatment of U2OS or MCF7 cells with DNA damaging agents (such as doxorubicin at 0.2 µg/ml) induces wild type p53 expression which in turn activates WAF1 expression. Serum stimulation of quiescent cells will give low level WAF1 expression independent of p53 expression. Untreated cells will express little p21WAF1 and can be used as a negative control. Cat. No. OP64F was tested in HALT cells induced by incubation at 31°C; FITC-goat anti-mouse IgG (Cat. No. DC13L) was used as a negative control. This antibody will immunoprecipitate p21WAF1 but not associated proteins. For immunoblotting applications, use a 0.22 µm filter and visualize by chemiluminescence. For staining paraffin sections, heating the tissue in 10 mM citrate buffer is required (see application references). In either paraffin or frozen sections of normal human colon, the non-dividing cells of colonic epithelium will stain positive for p21WAF1 while the proliferating compartment of crypts will not stain. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesAgarwal, M.L., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 8493.
      Chen, Y.Q., et al. 1995. Int. J. Oncology 7, 889.
      Deng, C., et al. 1995. Cell 82, 675.
      El-Deiry, W.S., et al. 1995. Cancer Res. 55, 2910.
      Waldman, T., et al. 1995. Cancer Res. 55, 5187.
      Elbendary, A., et al.1994. Cell Growth Diff. 5, 1301.
      El-Deiry, W.S., et al. 1994 Cancer Res. 54, 1169.
      Li, R., et al. 1994. Nature 371, 534.
      Michieli, P., et al. 1994. Cancer Res. 54, 3391.
      Noda, A., et al.1994. Exp. Cell Res. 211, 90.
      El-Deiry, W.S., et al.1993. Cell 75, 817.
      Gu, Y., et al. 1993. Nature 366, 707.
      Harper, J.W., et al.1993. Cell 75, 805.
      Xiong, Y., et al.1993. Genes Devel. 7, 1572.
      Xiong, Y., et al.1993. Nature 366, 701.
      Xiong, Y., et al.1992. Cell 71, 505.
      Application referencesEpitope Identification Patrick O'Connor (NCI, personal communication). Original Clone, Paraffin Sections, Frozen Sections El-Deiry, W.S., et al. 1995. Cancer Res. 55, 2910. Paraffin Sections, Antigen Retrieval Mouriaux, Frédéric, et al. 2000. Invest Ophthamol. Vis. Sci. 41, 2837. Flow Cytometry Carter, A., et al. 2004. Brit. J. Haematol. 127, 425.